Clinical Trials Logo

Advanced Biliary Tract Carcinoma clinical trials

View clinical trials related to Advanced Biliary Tract Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03092895 Completed - Clinical trials for Advanced Biliary Tract Carcinoma

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Start date: April 27, 2017
Phase: Phase 2
Study type: Interventional

This an open-label,Non-Randominzed Phase 2 study to evaluate the Safety and Tolerability of SHR-1210 in combination with Apatinib or chemotherapy (FOLFOX4 or GEMOX regimen) in subjects with Advanced PLC.or BTC Participants with advanced PLC who failed or intolerable to prior systemic therapy will be treated with SHR-1210 plus Apatinib; Participants with advanced PLC or BTC who have never received prior systemic therapy will be treated with SHR-1210 plus FOLFOX4 or GEMOX regimen.

NCT ID: NCT01828034 Completed - Clinical trials for Advanced Biliary Tract Carcinoma

First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

Start date: April 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test an investigational combination of drugs for bile duct or gallbladder cancers. Gemcitabine and cisplatin are two forms of chemotherapy commonly used in combination to treat bile duct and gallbladder cancers. The investigators are looking to improve treatment results. They will attempt to do so by adding the drug MEK162 to the treatment plan. MEK162 acts by blocking a protein called MEK 1/2 which helps cancer cells grow and divide. This study will help answer the question of whether MEK162 is a helpful drug in patients with bile duct or gallbladder cancers when given with gemcitabine and cisplatin.